The Synairgen share price is up 680% in a year! Should I buy now?

The Synairgen share price is exploding, as its new drug shows positive results. Is this a sign to buy? Zaven Boyrazian investigates.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The Synairgen (LSE:SNG) share price exploded over the last 12 months, increasing by over 680%. What caused this incredible growth? And should I be adding the stock to my growth portfolio? Let’s take a look.

Why did the Synairgen share price skyrocket?

Synairgen is a pharmaceutical drug development company that focuses on discovering new treatments for respiratory diseases. In 2020, it adapted its knowledge and talent to produce SNG001 – an advanced treatment for Covid-19 patients with severe symptoms.

There are numerous drugs already on the market to ease the impact of the virus. However, what makes SNG001 unique is the fact that it’s inhaled rather than injected. Thus the medicine can be directly absorbed into the lungs.

The primary catalyst behind Synairgen’s soaring share price was the announcement that SNG001 successfully completed its phase II trials. The results of which showed a 79% reduction in the need for ventilation machines amongst patients. Needless to say, the drug shows promise. And it would seem the FDA in the US agrees as it has greenlit the treatment for fast-track approval.

Last month, Synairgen began recruiting for phase II/III trials to gather more data and target patients at home instead of in a hospital environment.

If SNG001 is approved, City analysts have forecast that total revenue for 2021 will be around £150m, some £47m of which will be profit. Comparing that to Synairgen’s current share price places the P/E ratio at 7.4. To me, that looks relatively cheap for a high-growth biotech stock. But, as always, young drug development companies carry a lot of risk.

Discovering new medicines is a high-risk process

The results from the phase II trials are undoubtedly positive. However, they’re far from conclusive. After all, only 101 patients were involved in the study. As this sample size grows into the thousands for phase III, more accurate results will be acquired. And they may not be as positive as the earlier phases indicated.

It’s entirely possible for drugs in phase III to be rejected by regulators or simply become economically unviable after approval. This is particularly problematic for Synairgen as it has no other products in its portfolio.

The company has formed a handful of partnerships over the years and provides some service work. But ultimately, it lacks any form of reliable or recurring income. As such, it is continually having to raise additional funding to keep the lights on.

Suppose SNG001 fails to deliver the desired results? In that case, Synairgen will have to start the typical 10-year drug development cycle basically from scratch. As I don’t think investors are that patient, this will likely lead to a collapse in the Synairgen share price.

The Synairgen share price has many risks ahead

The bottom line

Personally, I think buying shares in Synairgen at its current price looks more like speculation than investing. The firm has many challenges ahead, and failing to overcome them could be catastrophic for the entire business.

For now, I’ll be keeping a close eye on it throughout 2021. But I’m not adding it to my portfolio yet.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Zaven Boyrazian does not own shares in Synairgen. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

British flag, Big Ben, Houses of Parliament and British flag composition
Investing Articles

Down 27% in 3 days! Should I buy the dip in this FTSE 250 defence stock?

This FTSE stock has collapsed in recent days, leaving this Fool wondering if he's looking at a buying opportunity for…

Read more »

Investing Articles

Is ITV a screaming FTSE 250 bargain hiding in plain sight?

Down by over two-thirds in around a decade, this well-known FTSE 250 share now trades on what may look like…

Read more »

Investing Articles

Is this FTSE 100 AI growth stock beginning to run out of steam?

Despite it being a runaway success, Andrew Mackie is becoming increasingly concerned for the momentum of this AI growth stock.

Read more »

Mature Caucasian woman sat at a table with coffee and laptop while making notes on paper
Investing Articles

Up 12% today, here’s a great FTSE 250 growth share to consider!

Softcat's share price is soaring following a blockbuster first-half trading announcement. Here's why the FTSE 250 share is worth a…

Read more »

Growth Shares

Prediction: in 1 year, the easyJet share price could be as high as…

Jon Smith points out why the easyJet share price could head higher over the coming year based on the current…

Read more »

Investing Articles

Up 21% with dividends on top! See the stunning Shell share price forecast for 2025

Brokers are feeling optimistic about the outlook for the Shell share price, predicting solid growth this year. But Harvey Jones…

Read more »

Investing Articles

£10,000 invested in AstraZeneca shares 1 year ago is now worth…

AstraZeneca shares have recovered from their brief slump with investors broadly buoyed by the company’s long-term business prospects.

Read more »

Investing Articles

What’s going on with Nvidia stock?

Nvidia stock has slumped, and it seems that CEO Jensen Huang may have lost the Midas touch after his AI…

Read more »